In vitro Activities and in vivo Recovery of Coagulation Factor IX Concentrates with a Hepatitis-Safe Concentrate

K.		Schimpf
B.		Westphal

Rehabilitation Hospital and Haemophilia Centre, Heidelberg Rehabilitation Foundation, Heidelberg, (FRG)

K. Schimpf, Rehabilitation Hospital and Haemophilia Centre, Heidelberg Rehabilitation Foundation, PO Box 101409, Heidelberg (FRG)

We compared PPSB concentrates from Intersero and Immuno, which have proved their efficacy in many treatments with a new PPSB concentrate produced by Biotest. In animal experiments, a reduction of the infectivity by at least 103-fold in comparison to normal pool concentrates was observed with this new concentrate. The measure units of bottles from the tested lots of the three preparations, declared to contain 500 units, were the following:

The in vivo recovery of factor IX calculated according to the actual bottle content, was 24 and 23% for the product of Biotest, Intersero and Immuno, respectively. The half-lives for factor IX, calculated from the values at 24 and 58 h, were 28, 28 and 32 h for the products of Biotest, Intersero and Immuno, respectively. A different factor IX reagent gave the following values: 24, 23 and 23 h.

25 units/kg body weight of each concentrate was injected into 6 non-bleeding volunteers with haemophilia B. Following the intravenous injection of the standard dose, calculated on the basis of one bottle containing 500 units of factor IX, the in vivo activities in percent measured 30 min after injection were as follows: